SHAREHOLDER ALERT: WeissLaw LLP Reminds COLB, XLRN, ACBI. and ECHO Shareholders About Its Ongoing Investigations

-

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Columbia Banking System, Inc. (NASDAQ: COLB)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Columbia Banking System, Inc. (NASDAQ: COLB) in connection with the proposed merger of the company with Umpqua Holdings Corporation ("Umpqua"). Under the terms of the merger agreement, Umpqua shareholders will receive 0.5958 of a share of COLB stock for each Umpqua share they own, representing implied per-share merger consideration of approximately $20.85 based upon COLB's October 26, 2021 closing price of $34.86 .  If you own COLB shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/colb

Acceleron Pharma Inc. (NASDAQ: XLRN)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Acceleron Pharma Inc. (NASDAQ: XLRN) in connection with the proposed acquisition of the Company by Merck & Co., Inc. ("Merck") (NYSE: MRK), via a tender offer. Under the terms of the merger agreement, XLRN shareholders will receive $180.00 per share in cash for each share of XLRN common stock that they hold.  If you own XLRN shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/xlrn

Atlantic Capital Bancshares, Inc. (NASDAQ: ACBI)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Atlantic Capital Bancshares, Inc. (NASDAQ: ACBI) in connection with the company's proposed acquisition by SouthState Corporation ("SouthState"). Pursuant to the merger agreement, ACBI shareholders will receive 0.36 shares of South State common stock for each ACBI share that they own, representing implied per-share merger consideration of approximately $27.93 based upon SouthState's October 26, 2021 closing price of $77.59 .  If you own ACBI shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/acbi

Echo Global Logistics, Inc. (NASDAQ: ECHO)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Echo Global Logistics, Inc. (NASDAQ: ECHO) in connection with the proposed acquisition of the company by funds managed by The Jordan Company, L.P. Under the terms of the merger agreement, ECHO shareholders will receive $48.25 per share in cash for each share of ECHO stock that they hold.  If you own ECHO shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/echo

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-reminds-colb-xlrn-acbi-and-echo-shareholders-about-its-ongoing-investigations-301410246.html

SOURCE WeissLaw LLP

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
SVN-114 selected as the lead candidate for PTSD discovery programme

SVN-114 selected as the lead candidate for PTSD discovery programme

Novel compound from patent-pending SVN-SDN-14 series targeting a major global mental health disorder

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces the selection of SVN-114 as the lead candidate from the Company's proprietary SVN-SDN-14 discovery... Keep Reading...
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused... Keep Reading...
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly owned... Keep Reading...
Box of Moderna COVID-19 vaccine vials with red caps and labels.

Moderna to Pay US$950 Million to Settle COVID-19 Vaccine Patent Dispute

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine.The pharmaceuticals giant announced it has reached a global settlement with Arbutus Biopharma (NASDAQ:ABUS) and Genevant Sciences GmbH over claims... Keep Reading...
Scientists examining a sample under a microscope in a lab setting.

Gilead to Acquire Arcellx in US$7.8 Billion Bet on Cancer Therapy

Gilead Sciences (NASDAQ:GILD) announced plans to acquire cancer immunotherapy partner Arcellx (NASDAQ:ACLX) in a deal worth up to US$7.8 billion, moving to take full control of their jointly developed multiple myeloma therapy anito-cel as it seeks to expand its oncology pipeline.The agreement,... Keep Reading...
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its second quarter of... Keep Reading...

Interactive Chart

Latest Press Releases

Related News